NYSE: ANROAlto Neuroscience Inc Stock
$14.18+0.05 (+0.35%)
Updated Apr 26, 2024
ANRO Price
$14.18
Fair Value Price
N/A
Market Cap
$381.21M
52 Week Low
$12.78
52 Week High
$24.00
P/E
-1.46x
P/B
-5.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$36.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.24
Operating Cash Flow
-$33M
Beta
-0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANRO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ANRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ANRO due diligence checks available for Premium users.
Be the first to know about important ANRO news, forecast changes, insider trades & much more!
ANRO News
Valuation
ANRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.46x
Industry
14.88x
Market
41.14x
ANRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.32x
Industry
5.85x
ANRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.2M
Profit Margin
0%
ANRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$86.6M
Liabilities
$16.8M
Debt to equity
-0.24
ANRO's short-term assets ($85.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANRO's short-term assets ($85.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.5M
Investing
-$352.0k
Financing
$43.1M
ANRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANRO vs Biotech Stocks
Alto Neuroscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.